AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9270567 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 125)
Number of subjects: 241
Study 2930837 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin (DNR) or 4‐(9‐acridinylamino)methanesulfan‐m‐anisidide (AMSA) in combination with arabinosylcytosine (Ara‐C) and 6‐thioguanine (TG)
Number of subjects: 57
Study 861135 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg digoxin tablets (Lanoxin)
Number of subjects: 10
Study 861135 — intervention group
Group type: COMPARATOR
Intervention: 0.2 mg digoxin in solution in soft gelatin capsules (Lanoxicaps)
Number of subjects: 10
Study 861135 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanoxicaps (0.2 mg)
Number of subjects: 10
Study 861135 — intervention group
Group type: COMPARATOR
Intervention: Lanoxin (0.25 mg)
Number of subjects: 10
Study 28448688 — intervention group
Group type: EXPERIMENTAL
Intervention: Evogliptin 5 mg
Number of subjects: 160
Study 28448688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 25872532 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine (25 mcg once daily, increased as needed to maintain TSH between 0.4 to 2.5 mU/L)
Number of subjects: 100
Study 25872532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 23868627 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplement containing Omega‐3, Policosanol, Resveratrol, L‐carnitine, Monascus purpureus, Coenzyme Q10, Vitamin B6 and Vitamin B12
Number of subjects: 80
Study 23868627 — intervention group
Group type: COMPARATOR
Intervention: Balanced diet and physical exercise (Control Group B)
Number of subjects: 80
Study 21944515 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression present
Number of subjects: 2220
Study 21944515 — intervention group
Group type: COMPARATOR
Intervention: Regression absent
Number of subjects: 2220
Study 19786418 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic Walking training
Number of subjects: 80
Study 19786418 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard rehabilitation programme)
Number of subjects: 80
Study 19786418 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking training group
Number of subjects: 80
Study 16679274 — intervention group
Group type: EXPERIMENTAL
Intervention: SIRRIM technique
Number of subjects: 24
Study 15575341 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal with dual-wave insulin bolus delivery
Number of subjects: 0
Study 15575341 — intervention group
Group type: COMPARATOR
Intervention: High-fat meal with normal insulin bolus delivery
Number of subjects: 0
Study 15575341 — intervention group
Group type: COMPARATOR
Intervention: Control meal with normal insulin bolus delivery
Number of subjects: 0
Study 11508020 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary Family Service Center project
Number of subjects: 80
Study 11508020 — intervention group
Group type: COMPARATOR
Intervention: Regular Head Start
Number of subjects: 80
Study 9422856 — intervention group
Group type: EXPERIMENTAL
Intervention: Anistreplase treatment
Number of subjects: 311
Study 9422856 — intervention group
Group type: COMPARATOR
Intervention: TPA versus streptokinase
Number of subjects: 311
Study 8236505 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 plus L-carnitine (1000 mg/day orally)
Number of subjects: 30
Study 8236505 — intervention group
Group type: COMPARATOR
Intervention: IL-2 alone
Number of subjects: 30
Study 3683810 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal word orientation
Number of subjects: 0
Study 3683810 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical word orientation
Number of subjects: 0
Study 3683810 — intervention group
Group type: EXPERIMENTAL
Intervention: Imageability with horizontal displays
Number of subjects: 0
Study 3683810 — intervention group
Group type: COMPARATOR
Intervention: Imageability effects between visual fields
Number of subjects: 0
Study 29326124 — intervention group
Group type: COMPARATOR
Intervention: Conventional tacrolimus/methotrexate (A)
Number of subjects: 138
Study 29326124 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib/tacrolimus/methotrexate (B)
Number of subjects: 138
Study 29326124 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib/sirolimus/tacrolimus (C)
Number of subjects: 138
Study 28403865 — intervention group
Group type: EXPERIMENTAL
Intervention: 360° Quantified Self (360QS) methodology using wearable sensors, mobile and social media for data collection.
Number of subjects: 50
Study 28403865 — intervention group
Group type: EXPERIMENTAL
Intervention: 360° Quantified Self (360QS) methodology
Number of subjects: 50
Study 26090707 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Tape (KT) application
Number of subjects: 27
Study 26090707 — intervention group
Group type: COMPARATOR
Intervention: No tape
Number of subjects: 27
Study 22464647 — intervention group
Group type: EXPERIMENTAL
Intervention: ILIT with MAT-Fel d 1
Number of subjects: 0
Study 22464647 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline in alum)
Number of subjects: 0
Study 20461089 — intervention group
Group type: EXPERIMENTAL
Intervention: GP-led melanoma follow-up
Number of subjects: 142
Study 18327427 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 15 mg/kg/day, twice a day
Number of subjects: 97
Study 18327427 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin 30-50 mg/kg/day, four times daily
Number of subjects: 97
Study 18327427 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 97
Study 18327427 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 97
Study 18327427 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin and Erythromycin
Number of subjects: 97
Study 16360994 — intervention group
Group type: EXPERIMENTAL
Intervention: IV NAC 300 mg
Number of subjects: 65
Study 16360994 — intervention group
Group type: EXPERIMENTAL
Intervention: IV NAC 600 mg
Number of subjects: 65
Study 16360994 — intervention group
Group type: COMPARATOR
Intervention: IV fluid alone (Control)
Number of subjects: 65
Study 12560887 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking group (11 subjects)
Number of subjects: 17
Study 12560887 — intervention group
Group type: COMPARATOR
Intervention: Resting group (6 subjects)
Number of subjects: 17
Study 10338049 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg/kg intravenous immunoglobulin
Number of subjects: 0
Study 10338049 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/kg intravenous immunoglobulin
Number of subjects: 0
Study 8620338 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol (20 g/d)
Number of subjects: 8
Study 8620338 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol (20 g/d) + Simvastatin (20 mg/d)
Number of subjects: 8
Study 2015715 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative and postoperative intravenous urokinase
Number of subjects: 344
Study 2015715 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term sodium warfarin therapy
Number of subjects: 344
Study 2015715 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment mentioned)
Number of subjects: 344
Study 7006581 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol alone, supplemented after two weeks with epinephrine
Number of subjects: 16
Study 7006581 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine treatment alone
Number of subjects: 16
Study 7006581 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous timolol treatment with epinephrine
Number of subjects: 16
Study 7006581 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol and epinephrine combined therapy
Number of subjects: 16
Study 30614289 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg) plus Myoinositol (600 mg) three times a day
Number of subjects: 120
Study 30614289 — intervention group
Group type: COMPARATOR
Intervention: Metformin (500 mg) three times a day
Number of subjects: 120
Study 28550080 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive phosphate goal of 2.33‐4.66 mg/dl (0.75‐1.50 mmol/L)
Number of subjects: 104
Study 28550080 — intervention group
Group type: COMPARATOR
Intervention: Liberalized target of 6.20‐7.75 mg/dl (2.00‐2.50 mmol/L)
Number of subjects: 104
Study 25525835 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic mixture (9 g of galactooligosaccharides [GOS] + 1 g of maltodextrins; daily for 5 days)
Number of subjects: 0
Study 25525835 — intervention group
Group type: COMPARATOR
Intervention: Control medium (in vitro)
Number of subjects: 0
Study 23831050 — intervention group
Group type: EXPERIMENTAL
Intervention: ARP1 (15-30 mg/kg/day)
Number of subjects: 176
Study 23831050 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 176
Study 21331949 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tryptophan (Trp) and arginine (Arg) in diet
Number of subjects: 0
Study 21331949 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 19127071 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to 4,000 grains/m3 of JC pollen
Number of subjects: 24
Study 19127071 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to 8,000 grains/m3 of JC pollen
Number of subjects: 24
Study 19127071 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to 12,000 grains/m3 of JC pollen
Number of subjects: 24
Study 19127071 — intervention group
Group type: COMPARATOR
Intervention: Exposure to 0 grains/m3 of JC pollen
Number of subjects: 24
Study 19127071 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of symptoms between summer and winter studies
Number of subjects: 24
Study 17942035 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride (50 mg/8 h)
Number of subjects: 120
Study 17942035 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg/24 h)
Number of subjects: 120
Study 17942035 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride (50 mg/8 h) plus Melatonin (3 mg/24 h)
Number of subjects: 120
Study 17942035 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose 50 mg/8 h)
Number of subjects: 120
Study 15864246 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 4395
Study 15864246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4395
Study 12081590 — intervention group
Group type: EXPERIMENTAL
Intervention: Ash-Split catheter (MedComp)
Number of subjects: 132
Study 12081590 — intervention group
Group type: COMPARATOR
Intervention: Opti-Flow catheter (Bard Access Systems)
Number of subjects: 132
Study 9651260 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous heroin (median 480 mg daily) and health/psychosocial services
Number of subjects: 51
Study 9651260 — intervention group
Group type: COMPARATOR
Intervention: Conventional drug treatment (usually methadone maintenance)
Number of subjects: 51
Study 9651260 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous heroin
Number of subjects: 51
Study 9651260 — intervention group
Group type: COMPARATOR
Intervention: Conventional drug treatment
Number of subjects: 51
Study 8580671 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 29
Study 8580671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 2693013 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 h/wk training program (exercise group)
Number of subjects: 32
Study 2693013 — intervention group
Group type: COMPARATOR
Intervention: Nonphysical activities (nonexercise group)
Number of subjects: 32
Study 910806 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte transfusions
Number of subjects: 30
Study 910806 — intervention group
Group type: COMPARATOR
Intervention: Control group (no transfusions)
Number of subjects: 30
Study 31611547 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized 3D-printed single-sided lateral wedge insole (CLWI)
Number of subjects: 30
Study 31611547 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional single insert
Number of subjects: 30
Study 31611547 — intervention group
Group type: COMPARATOR
Intervention: Unilateral flat insoles (Control)
Number of subjects: 30
Study 27517267 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1
Number of subjects: 383
Study 27517267 — intervention group
Group type: COMPARATOR
Intervention: Taxane
Number of subjects: 383
Study 26494444 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 4.5 mg/kg
Number of subjects: 13
Study 23100117 — intervention group
Group type: EXPERIMENTAL
Intervention: E10.5% probiotic
Number of subjects: 200
Study 23100117 — intervention group
Group type: EXPERIMENTAL
Intervention: E21.5% probiotic
Number of subjects: 200
Study 23100117 — intervention group
Group type: EXPERIMENTAL
Intervention: E32.0% probiotic
Number of subjects: 200
Study 23100117 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0% probiotic
Number of subjects: 200
Study 23100117 — intervention group
Group type: EXPERIMENTAL
Intervention: All experimental groups (E10.5%, E21.5%, E32.0%)
Number of subjects: 200
Study 23100117 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 200
Study 21148765 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg)
Number of subjects: 10
Study 21148765 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sucrose)
Number of subjects: 10
Study 18974711 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) for 11 weeks, consisting of 30 inspiratory efforts performed twice a day
Number of subjects: 15
Study 18974711 — intervention group
Group type: COMPARATOR
Intervention: Control group (basic training only)
Number of subjects: 15
Study 18974711 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 15
Study 16669849 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (10-40 mg day-1)
Number of subjects: 171
Study 12792293 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 30
Study 11111206 — intervention group
Group type: EXPERIMENTAL
Intervention: α1-blockers
Number of subjects: 0
Study 11111206 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-hypertensive α1-blockers (terazosin and doxazosin)
Number of subjects: 0
Study 11111206 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin and tamsulosin
Number of subjects: 0
Study 11111206 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 0
Study 8975873 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-gamma (IFN-gamma)
Number of subjects: 18
Study 8975873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 1280145 — intervention group
Group type: EXPERIMENTAL
Intervention: Inerpan
Number of subjects: 62
Study 1280145 — intervention group
Group type: COMPARATOR
Intervention: Conventional dressings (petroleum jelly gauze, petroleum jelly gauze with antibiotics, silver sulphadiazine cream)
Number of subjects: 62
Study 3871597 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous prophylaxis with trimethoprim‐sulfamethoxazole
Number of subjects: 38
Study 3871597 — intervention group
Group type: COMPARATOR
Intervention: Intermittent self‐administered therapy (single‐dose trimethoprim‐sulfamethoxazole)
Number of subjects: 38
Study 3871597 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-administered therapy with single-dose trimethoprim‐sulfamethoxazole
Number of subjects: 38
Study 29128419 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 0
Study 29128419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27630009 — intervention group
Group type: EXPERIMENTAL
Intervention: READY-Girls preconception counseling (RGPC)
Number of subjects: 136
Study 27630009 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 136
Study 24576793 — intervention group
Group type: EXPERIMENTAL
Intervention: Drospirenone-containing combined oral contraceptives (DRSP24d)
Number of subjects: 85109
Study 24576793 — intervention group
Group type: EXPERIMENTAL
Intervention: Drospirenone-containing combined oral contraceptives (DRSP21d)
Number of subjects: 85109
Study 24576793 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-drospirenone oral contraceptives (non-DRSP)
Number of subjects: 85109
Study 24576793 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-containing oral contraceptives (LNG)
Number of subjects: 85109
Study 22491665 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracotomy
Number of subjects: 198
Study 22491665 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic surgery (VATS)
Number of subjects: 198
Study 22491665 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical procedures (overall)
Number of subjects: 198
Study 22491665 — intervention group
Group type: COMPARATOR
Intervention: Non-screening series (comparison)
Number of subjects: 198
Study 20146168 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone replacement therapy (GHRT)
Number of subjects: 15
Study 20146168 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 15
Study 18780883 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy (CIMT)
Number of subjects: 0
Study 15747701 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 90
Study 15747701 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 90
Study 15747701 — intervention group
Group type: COMPARATOR
Intervention: Sedation with alfentanil and midazolam plus paracervical block
Number of subjects: 90
Study 15747701 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation with remifentanil plus paracervical block
Number of subjects: 90
Study 15333399 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzydamine hydrochloride (BH) - four puffs applied to the pharynx 30 min before operation and 5 min before induction of anesthesia.
Number of subjects: 100
Study 15333399 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (control) - applied with the same protocol as BH.
Number of subjects: 100
Study 11144372 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP/HepB vaccine used to reconstitute lyophilized PRP‐T vaccine administered as a single injection
Number of subjects: 405
Study 11144372 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP/HepB vaccine and PRP‐T vaccine administered as two separate injections
Number of subjects: 405
Study 11144372 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP, HepB and PRP‐T vaccines administered as three separate injections
Number of subjects: 405
Study 11144372 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of Hib conjugate vaccine given at 11 to 15 months of age
Number of subjects: 405
Study 9122732 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-2 (rIL-2)
Number of subjects: 0
Study 9122732 — intervention group
Group type: COMPARATOR
Intervention: recombinant interleukin-2 (rIL-2) with coadministration of lymphokine-activated killer (LAK) cells
Number of subjects: 0
Study 8330602 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 4 micrograms kg‐1 (n = 33)
Number of subjects: 65
Study 8330602 — intervention group
Group type: COMPARATOR
Intervention: Morphine 50 micrograms kg‐1 (n = 32)
Number of subjects: 65
Study 3781681 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% plain
Number of subjects: 75
Study 3781681 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% with epinephrine 1:100,000
Number of subjects: 75
Study 3781681 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine 1:20,000
Number of subjects: 75
Study 3781681 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention specified)
Number of subjects: 75
Study 30834513 — intervention group
Group type: EXPERIMENTAL
Intervention: ATB‐346 (250 mg once daily)
Number of subjects: 244
Study 30834513 — intervention group
Group type: COMPARATOR
Intervention: naproxen (550 mg twice daily)
Number of subjects: 244
Study 29523571 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT) for 4-6 weeks
Number of subjects: 40
Study 29523571 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 40
Study 27502865 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glucose-insulin-potassium (GIK)
Number of subjects: 0
Study 27502865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27502865 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK
Number of subjects: 0
Study 25335328 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiangzhi Tongluo Soft Capsule (JTSC) combined with Atorvastatin Calcium Tablet (ACT)
Number of subjects: 138
Study 25335328 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin Calcium Tablet (ACT) alone
Number of subjects: 138
Study 22215753 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased lactate dehydrogenase (≥ 2 × upper limit of normal [ULN])
Number of subjects: 0
Study 22215753 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary site involvement
Number of subjects: 0
Study 22215753 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow/CNS positive disease
Number of subjects: 0
Study 22215753 — intervention group
Group type: COMPARATOR
Intervention: Age (≥ 15 years)
Number of subjects: 0
Study 19717477 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin clavulanate (n = 212)
Number of subjects: 427
Study 19717477 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (n = 215)
Number of subjects: 427
Study 19717477 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin for predominantly 5 days (n = 127)
Number of subjects: 427
Study 19717477 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin for predominantly 10 days (n = 87)
Number of subjects: 427
Study 18511873 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 1095
Study 18511873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1095
Study 16007327 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly ibandronate 50 mg/50 mg
Number of subjects: 1609
Study 16007327 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly ibandronate 100 mg
Number of subjects: 1609
Study 16007327 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly ibandronate 150 mg
Number of subjects: 1609
Study 16007327 — intervention group
Group type: COMPARATOR
Intervention: Daily ibandronate 2.5 mg
Number of subjects: 1609